United Therapeutics Corporation (UTHR) Rating Reiterated by Cowen and Company

United Therapeutics Corporation (NASDAQ:UTHR)‘s stock had its “hold” rating reissued by equities researchers at Cowen and Company in a research note issued to investors on Friday, October 27th. They currently have a $129.00 price target on the biotechnology company’s stock. Cowen and Company’s price objective points to a potential upside of 6.61% from the company’s current price.

UTHR has been the subject of several other research reports. UBS AG reaffirmed a “sell” rating and set a $106.00 price target on shares of United Therapeutics Corporation in a research report on Thursday, July 6th. ValuEngine raised shares of United Therapeutics Corporation from a “buy” rating to a “strong-buy” rating in a research report on Thursday, July 13th. BidaskClub lowered shares of United Therapeutics Corporation from a “buy” rating to a “hold” rating in a research report on Wednesday, July 19th. Jefferies Group LLC reaffirmed a “sell” rating and set a $105.00 price target on shares of United Therapeutics Corporation in a research report on Friday, July 14th. Finally, Zacks Investment Research lowered shares of United Therapeutics Corporation from a “hold” rating to a “sell” rating in a research report on Thursday, July 13th. Five investment analysts have rated the stock with a sell rating, seven have given a hold rating and three have given a buy rating to the company. The stock presently has a consensus rating of “Hold” and a consensus price target of $132.82.

Shares of United Therapeutics Corporation (NASDAQ UTHR) traded down $0.23 during midday trading on Friday, hitting $121.00. 190,600 shares of the company’s stock traded hands, compared to its average volume of 569,661. United Therapeutics Corporation has a 12 month low of $112.01 and a 12 month high of $169.89. The stock has a market capitalization of $5,238.48, a P/E ratio of 10.69 and a beta of 1.38.

United Therapeutics Corporation (NASDAQ:UTHR) last posted its quarterly earnings data on Wednesday, October 25th. The biotechnology company reported $6.27 earnings per share for the quarter, beating analysts’ consensus estimates of $4.01 by $2.26. The business had revenue of $445.50 million during the quarter, compared to analyst estimates of $426.43 million. United Therapeutics Corporation had a net margin of 30.50% and a return on equity of 26.24%. The company’s revenue was up 9.1% on a year-over-year basis. During the same quarter in the previous year, the business posted $4.23 earnings per share. analysts predict that United Therapeutics Corporation will post 11.92 earnings per share for the current year.

TRADEMARK VIOLATION NOTICE: This report was originally reported by StockNewsTimes and is the sole property of of StockNewsTimes. If you are reading this report on another domain, it was illegally stolen and republished in violation of US & international trademark and copyright legislation. The correct version of this report can be viewed at https://stocknewstimes.com/2017/11/11/united-therapeutics-corporation-uthr-rating-reiterated-by-cowen-and-company.html.

In other United Therapeutics Corporation news, Director Christopher Causey sold 580 shares of the stock in a transaction on Thursday, September 7th. The shares were sold at an average price of $134.48, for a total transaction of $77,998.40. Following the sale, the director now directly owns 3,295 shares of the company’s stock, valued at $443,111.60. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, CEO Martine A. Rothblatt sold 1,232 shares of the stock in a transaction on Thursday, September 7th. The stock was sold at an average price of $133.32, for a total transaction of $164,250.24. Following the sale, the chief executive officer now directly owns 2,301 shares in the company, valued at $306,769.32. The disclosure for this sale can be found here. Insiders have sold a total of 16,793 shares of company stock worth $2,081,621 over the last quarter. 7.80% of the stock is currently owned by insiders.

Institutional investors have recently added to or reduced their stakes in the business. State of Wisconsin Investment Board acquired a new position in United Therapeutics Corporation during the 2nd quarter valued at about $5,256,000. Comerica Bank boosted its position in shares of United Therapeutics Corporation by 1.3% during the 2nd quarter. Comerica Bank now owns 35,249 shares of the biotechnology company’s stock valued at $4,635,000 after purchasing an additional 458 shares in the last quarter. River & Mercantile Asset Management LLP bought a new position in shares of United Therapeutics Corporation during the 2nd quarter valued at about $908,000. Sumitomo Mitsui Trust Holdings Inc. boosted its position in shares of United Therapeutics Corporation by 2.3% during the 2nd quarter. Sumitomo Mitsui Trust Holdings Inc. now owns 123,016 shares of the biotechnology company’s stock valued at $15,959,000 after purchasing an additional 2,762 shares in the last quarter. Finally, Captrust Financial Advisors bought a new position in shares of United Therapeutics Corporation during the 2nd quarter valued at about $925,000.

About United Therapeutics Corporation

United Therapeutics Corporation is a biotechnology company. The Company is focused on the development and commercialization of products for the treatment of chronic and life-threatening conditions. The Company markets and sells four commercial therapies in the United States to treat pulmonary arterial hypertension (PAH): Remodulin (treprostinil) Injection; Tyvaso (treprostinil) Inhalation Solution (Tyvaso); Orenitram (treprostinil) Extended-Release Tablets (Orenitram); and Adcirca (tadalafil) Tablets (Adcirca).

Analyst Recommendations for United Therapeutics Corporation (NASDAQ:UTHR)

Receive News & Ratings for United Therapeutics Corporation Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for United Therapeutics Corporation and related companies with MarketBeat.com's FREE daily email newsletter.

Latest News

Leave a Reply